

PATENT

07 DEC 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Branellec, Didler et al

Examiner:

Art Unit:

Serial No.: **09/787,995**

Filed: **March 23, 2001**

Title: **USE OF SPECIFIC HYBRID
PROMOTERS FOR CONTROLLING
TISSUE EXPRESSION**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
Express Mail in an envelope addressed to
Commissioner for Patents, Washington, D.C. 20231, on

12-7-01
Date of Deposit
Denise L. Walker
Signature

EK897872141US

Express Mail No.

**STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)**

Commissioner for Patents

Washington, D.C. 20231

Sir:

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the "Sequence Listing" and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same; and (2) the content of the substitute copy of the Sequence Listing and the computer readable copies required by 37 C.F.R. 1.821 (e) contain no new matter. Support for the Amendments can be found in the application as filed.

Respectfully submitted,

T. Helen Payne
T. Helen Payne, Reg. No. 36,889
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-5789
Telefax (908) 231-2626

Aventis Docket No. ST98032